Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)
Close on Nov 17, 2026Market cap $792.02MP/E –Yield –
Lexicon Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lexicon Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$54.02M. For fiscal 2025 it was -$48.29M. The highest annual figure on record is $145.10M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.29M | – |
| FY2024 | Dec 31, 2024 | -$196.58M | – |
| FY2023 | Dec 31, 2023 | -$171.20M | – |
| FY2022 | Dec 31, 2022 | -$100.33M | – |
| FY2021 | Dec 31, 2021 | -$86.80M | – |
| FY2020 | Dec 31, 2020 | -$44.87M | -130.9% |
| FY2019 | Dec 31, 2019 | $145.10M | – |
| FY2018 | Dec 31, 2018 | -$99.60M | – |
| FY2017 | Dec 31, 2017 | -$127.23M | – |
| FY2016 | Dec 31, 2016 | -$125.12M | -5800.0% |
| FY2015 | Dec 31, 2015 | $2.20M | – |
| FY2014 | Dec 31, 2014 | -$98.44M | – |
| FY2013 | Dec 31, 2013 | -$99.51M | – |
| FY2012 | Dec 31, 2012 | -$104.23M | – |
| FY2011 | Dec 31, 2011 | -$109.21M | – |
| FY2010 | Dec 31, 2010 | -$90.32M | – |
| FY2009 | Dec 31, 2009 | -$83.80M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.44M | -775.8% |
| Q1 FY2026 | Mar 31, 2026 | -$886.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.04M | – |
| Q2 FY2025 | Jun 30, 2025 | $3.91M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.50M | – |
| Q4 FY2024 | Dec 31, 2024 | -$32.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$63.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$55.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$45.19M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.59M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.48M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.18M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.27M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.22M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.86M | -126.1% |
| Q2 FY2021 | Jun 30, 2021 | -$17.92M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.11M | – |
| Q3 FY2020 | Sep 30, 2020 | $87.46M | -61.2% |
| Q2 FY2020 | Jun 30, 2020 | -$63.68M | – |
| Q1 FY2020 | Mar 31, 2020 | -$61.53M | – |
| Q4 FY2019 | Dec 31, 2019 | -$46.28M | – |
| Q3 FY2019 | Sep 30, 2019 | $225.58M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.57M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.46M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.01M | – |
| Q2 FY2018 | Jun 30, 2018 | -$29.34M | – |
| Q1 FY2018 | Mar 31, 2018 | -$36.79M | – |
| Q4 FY2017 | Dec 31, 2017 | -$28.09M | – |
| Q3 FY2017 | Sep 30, 2017 | -$27.68M | – |
| Q2 FY2017 | Jun 30, 2017 | -$32.57M | – |
| Q1 FY2017 | Mar 31, 2017 | -$38.88M | – |
| Q4 FY2016 | Dec 31, 2016 | -$30.82M | – |
| Q3 FY2016 | Sep 30, 2016 | -$34.42M | – |
See a number that looks wrong?